For patients who are not eligible for SCT, using a molecular switch to terminate CAR T cells, or early infusion with purified CD34+ stem cells to promote T-cell recovery, may be the alternative strategies to reduce the risk of severe infections [20]. This evidence concerns the gene CD34 and infection.